Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Bionano Genomics, Inc. (BNGO) had Stock-Based Compensation of $0.67M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$6.69M |
|
$-8.30M |
|
$3.44M |
|
$3.25M |
|
$14.58M |
|
$-7.90M |
|
$-0.40M |
|
$-8.29M |
|
$-8.29M |
|
$-8.30M |
|
$-8.30M |
|
$-8.30M |
|
$-8.30M |
|
$-7.90M |
|
$-5.73M |
|
10.98M |
|
10.98M |
|
$-0.76 |
|
$-0.76 |
|
| Balance Sheet Financials | |
$38.98M |
|
$14.04M |
|
$25.83M |
|
$64.80M |
|
$21.23M |
|
$3.46M |
|
$6.11M |
|
$27.34M |
|
$37.46M |
|
$34.46M |
|
$37.46M |
|
11.28M |
|
| Cash Flow Statement Financials | |
$-5.72M |
|
$5.46M |
|
$0.66M |
|
$4.51M |
|
$4.91M |
|
$0.40M |
|
|
Stock-Based Compensation |
$0.67M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.84 |
|
-- |
|
-- |
|
0.08 |
|
0.37 |
|
48.63% |
|
-118.09% |
|
-118.09% |
|
-- |
|
-124.02% |
|
-124.17% |
|
$-5.72M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.65 |
|
1.62 |
|
55.63 |
|
-22.16% |
|
-24.10% |
|
-12.81% |
|
-20.29% |
|
$3.32 |
|
$-0.52 |
|
$-0.52 |
|